# China NMPA Inspection - Shenzhen Liuliguang Biotechnology Co., Ltd. - September 29, 2018

Source: https://www.globalkeysolutions.net/records/china_inspection/shenzhen-liuliguang-biotechnology-co-ltd/334c1ecb-e16b-496f-a1ed-1bc6ac344f66/
Source feed: China

> China NMPA unannounced inspection for Shenzhen Liuliguang Biotechnology Co., Ltd. published September 29, 2018. Shenzhen Liuliguang Biotechnology Co., Ltd. was subject to an unannounced inspection by the National Food and Drug Administration (NMPA) and the Guang

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Notification of Unannounced Inspection of Shenzhen Liuliguang Biotechnology Co., Ltd.
- Company Name: Shenzhen Liuliguang Biotechnology Co., Ltd.
- Publication Date: 2018-09-29
- Product Type: Cosmetics
- Summary: Shenzhen Liuliguang Biotechnology Co., Ltd. was subject to an unannounced inspection by the National Food and Drug Administration (NMPA) and the Guangdong Provincial Food and Drug Administration. Conducted based on the "Key Points for Cosmetic Production License Inspection," the inspection identified seven deficiencies, comprising two serious defects and five general defects. A critical finding, explicitly marked as a serious defect, was the company's unstandardized batch definition, highlighted by large quantities of unlabeled lyophilized powder vials in the raw material warehouse, which hindered effective product identification.

Additional significant issues included the lack of pressure differential and maintenance records for air purification filters, and inadequate warehouse space. Raw material management suffered from inconsistent or missing location cards, discrepancies in recorded weights, and improper storage conditions—specifically, arbutin requiring refrigeration was stored at room temperature. The company's re-evaluation process for expired raw materials was deemed insufficient, with critical indicators not tested. Furthermore, finished product sample retention quantities were inadequate, failing to meet regulatory requirements.

As a result, the Guangdong Provincial Food and Drug Administration has ordered Shenzhen Liuliguang Biotechnology Co., Ltd. to rectify all identified problems within a specified period and submit a comprehensive rectification report to the Drug and Chemical Supervision Department of the State Administration for Market Regulation within two months.

Company: https://www.globalkeysolutions.net/companies/shenzhen-liuliguang-biotechnology-co-ltd/e9ab5fdf-6567-4e63-a403-7bfe238b7cae/